ArticleInternational journal of molecular sciences2026
Population Frequencies of VWD-Associated Genotypes: Cross-Resource Evidence from RGC-ME and gnomAD.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Population-scale sequencing can quantify genotypes associated with von Willebrand disease (VWD), but these frequencies cannot be translated directly into clinically manifest disease without phenotype and penetrance data. We therefore estimated subtype-specific VWD-associated genotype frequencies in RGC-ME, compared them with gnomAD, and examined which analytical assumptions limit clinical interpretation. Germline VWF variants classified in ClinVar as pathogenic or likely pathogenic (P/LP) on 1 August 2026 were normalized to GRCh38 and matched exactly to both resources. Subtypes were assigned only from unambiguous ClinVar phenotypes, and expected genotype frequencies were calculated from cumulative allele frequencies under dominant or recessive models. ClinVar contained 459 unique sequence-level P/LP alleles; 116 were shared by RGC-ME and gnomAD, 20 occurred only in RGC-ME, 68 only in gnomAD, and 255 in neither extract. The expected RGC-ME genotype frequencies per million individuals were 198, 16, 43, and 224 for types 1, 2A, 2B, and 2M, respectively, and 22.88 and 0.008 for types 2N and 3. Corresponding RGC-ME/gnomAD ratios ranged from 0.753 to 0.911. Shared allele frequencies were strongly concordant (Pearson r = 0.933; Spearman ρ = 0.887), although 238/459 alleles lacked an unambiguous subtype assignment. The cumulative frequency of P/LP VWF alleles was similar across resources, whereas subtype-specific expected genotype frequencies varied with phenotype annotation, the contribution of recurrent alleles, inheritance assumptions, and incomplete variant capture. Population databases can therefore quantify allele burden and model the frequency of VWD-associated genotypes, but clinical registries are required to determine penetrance, genotype-phenotype relationships, and the prevalence of clinically diagnosed VWD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.